Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine

Grants

Funding Acknowledgements

Maria Prins was a Senior Visiting Fellow at the Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, NSW, Australia when she drafted parts of the manuscript. We thank Campbell Aitken (Burnet Institute, Australia), Jennifer Evans (University of California San Francisco, USA), Thijs van de Laar (Amsterdam Public Health Service, Netherlands), Bart Grady (Amsterdam Public Health Service, Netherlands), and Charlotte van den Berg (Amsterdam Public Health Service, Netherlands) for assisting with the preparation of data; and Tanya Applegate (Kirby Institute for Infection and Immunity in Society, Australia) for her constructive comments during the preparation of this report. This report was funded by the Australian Government Department of Health and Ageing. The views expressed in this report do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. MP was supported by the Public Health Service of Amsterdam. MH was supported by a National Health and Medical Research Council Senior Researcher Fellowship. ALC and WOO were supported by the US National Institutes of Health (U19 A1040035 and R01 A1077757), the Damon Runyon Foundation, and the Dana Foundation. GL is supported by the US National Institutes of Health (U19 A1066345 and U19 A1082630). KP was supported by US National Institutes of Health (5R01DA016017 and 1R01DA031056-01A1) and the UCSF Liver Center (UCSF P30 DK026743). ARL and GJD were supported by National Health and Medical Research Council Practitioner Fellowships.